Physician-Owned Practice Reinforces Commitment to Physician Leadership

Florida Cancer Specialists & Research Institute Announces 2025-2026 Physician Leadership Appointments

Fort Myers, Fla., September 11, 2025 – Florida Cancer Specialists & Research Institute, LLC (FCS) announces appointments to physician leadership roles within the statewide practice.

“The evolution of our physician leadership roles reflects the growing depth, breadth, and diversity of expertise across our cancer program,” said Lucio N. Gordan, MD, FCS president & managing physician. “By bringing together physicians from a wide range of specialties, we continue to strengthen our ability to deliver the most advanced treatment modalities through a truly multidisciplinary approach.”

Sachin Kamath, MD, medical director of radiation oncology, has expanded his role to encompass radiology administration. Anton Serafini, MD has been named medical director of clinical radiology. Both are board-certified radiation oncologists.

Dr. Kamath joined FCS in 2015 and has contributed to ongoing advancements in the delivery of evidence-based treatments such as stereotactic radiosurgery and radiotherapy, including radiopharmaceuticals. He contributes widely to clinical research and has earned multiple honors. Dr. Kamath completed his medical training at the University of Florida at Gainesville.

In addition to several faculty appointments, Dr. Serafini has served throughout his career in key leadership positions in private practice, academic and hospital settings. He received his medical degree with research distinction from the University of Miami School of Medicine and was named as chief resident in nuclear medicine during his five-year combined residency in diagnostic radiology and nuclear medicine at Jackson Memorial Hospital in Miami. He joined FCS in 2024.

Dr. Kamath and Dr. Serafini are among six medical directors at FCS:

• Wilfredo Blasini, MD, FACP – Medical Director, Central Pathology
• Sachin Kamath, MD – Medical Director, Radiation Oncology & Radiology Administration
• Bradley Monk, MD – Medical Director, Late-Phase Clinical Research
• Manish R. Patel, MD – Medical Director, Drug Development
• Anton Serafini, MD – Medical Director, Clinical Radiology
• Jessica Stine, MD – Medical Director, Gynecologic Oncology

As a physician-owned practice, FCS is guided by the principle that physician leadership is essential to advancing exceptional cancer care. In alignment with this commitment, the following medical oncologists and hematologists were confirmed to directorship positions for the 2025-2026 term:

• Luis Carrascosa, MD –Radiopharmaceutical Therapy
• Matthew Fink, MD –Physician Compensation & Finance
• Gustavo Fonseca, MD, FACP –Research & Clinical Trials
• Alexander Glick, MD –Pharmacy & Therapeutics
• Maen Hussein, MD –Value-Based Care
• Scott Lunin, MD –Physician Engagement
• Richard McDonough, MD –Advocacy & Policy
• Ke Ning, MD –Cell Therapy
• Ameet Patel, MD –Cell Therapy
• Anjan Patel, MD –Pharmacy & Therapeutics
• Shachar Peles, MD –Cell Therapy
• Frank Rodriguez, MD –Physician Engagement

Committee leadership appointments include:

• Lucio N. Gordan, MD, FCS president & managing physician – Disciplinary & Ethics chair
• David Wenk, MD, FCS assistant managing physician – Compensation & Finance co-chair
• Jorge Ayub, MD, medical oncologist/hematologist – Quality chair
• Matthew Fink, MD, medical oncologist/hematologist – Compensation & Finance co-chair
• Sachin Kamath, MD, radiation oncologist – Compliance chair
• Paresh Patel, MD, medical oncologist/hematologist – Quality vice chair

FCS Chief Executive Officer Ryan Ciarrocchi noted, “The strength of the collaborative partnership between our physician leaders and executive management ensures that every FCS patient benefits from the collective expertise of our entire care team, with one shared goal: doing what is best for each individual we serve.”